Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 277 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in... September 22, 2021 Woman Helps Students With Special Needs Achieve Success After Graduation December 23, 2021 New targeted lung cancer screening programme on the horizon September 29, 2022 Easing Concerns about Giving Research Study Participants Their Genetic Test Results June 1, 2018 Load more HOT NEWS What to Know About At-Home DNA Tests for Detecting Cancer Risk EMA Recommends Extending Indications for Durvalumab How Running and Training for a Marathon Helped Me Cope After... She Faced Breast Cancer At 16 With Little Help From Doctors....
